Friday April 26, 2019

Study: Experimental Drug can Halt Parkinson’s Progression

The drug, named NLY01, is similar to compounds used to treat diabetes and is expected to move to clinical trials this year

0
//
Your work emails can affect your health, relationships
Your work emails can affect your health, relationships Pixabay

US researchers have developed an experimental drug that potentially slows down the progression of Parkinson’s disease as well as its symptoms.

In experiments performed with cultures of human brain cells and live mouse models, researchers from the Johns Hopkins University in Maryland reported that the drug blocked the degradation of brain cells that is the hallmark of Parkinson’s disease.

“It is amazingly protective of target nerve cells,” said Ted Dawson, Professor at the University’s School of Medicine.

The drug, named NLY01, is similar to compounds used to treat diabetes and is expected to move to clinical trials this year.

If successful in humans, it could be one of the first treatments to directly target the progression of Parkinson’s, not just the muscle rigidity, spasmodic movements, fatigue, dizziness, dementia and other symptoms of the disorder, Dawson said in the paper published in the journal Nature Medicine.

Parkinsons
Representational image. (IANS)

In a preliminary experiment in laboratory-grown human brain cells, Dawson’s team treated human microglia — a brain cell type that sends signals throughout the central nervous system in response to infection or injury — with NLY01 and found that they were able to turn the activating signals off.

Further, the researchers injected the mice with alpha-synuclein — the protein known to be the primary driver of Parkinson’s disease — and the mice treated with NLY01 maintained normal physical function and had no loss of dopamine neurons, indicating that the drug protected against the development of Parkinson’s disease.

Also Read: Fruit Bats Identified As Source Of Nipah Virus Outbreak in Kerala

In another experiment, the team used mice that were genetically engineered to naturally produce more human-type alpha-synuclein typically used to model human Parkinson’s disease that runs in families.

While under normal conditions, these so-called transgenic mice will succumb to the disease in 387 days, those treated with NLY01 extended the lives by over 120 days.

However, the experimental drug must still be tested for safety as well as effectiveness in people, Dawson cautioned. (IANS)

Next Story

Researchers To Develop Novel Therapy For Treating Parkinson’s Disease

Researchers developing new therapy to treat Parkinson's disease

0
10 million people living worldwide suffer from Parkinson;s disease Pixabay
10 million people living worldwide suffer from Parkinson;s disease Pixabay

Cell replacement may play an increasing role in alleviating the symptoms such as movement problems and memory loss of Parkinson’s disease (PD), researchers say.

The most common PD treatment today is based on enhancing the activity of the nigrostriatal pathway in the brain with dopamine-modulating therapies, thereby increasing striatal dopamine levels and improving motor impairment associated with the disease.

However, this treatment has significant long-term limitations and side effects.

“We are in desperate need of a better way of helping people with PD. It is on the increase worldwide. There is still no cure, and medications only go part way to fully treat incoordination and movement problems,” said Claire Henchcliffe, MD, from Weill Cornell Medicine in the US.

Parkinsons
Parkinson’s is caused by a lack of dopamine made by brain cells. (IANS)

Recent strides in stem cell technology mean that quality, consistency, activity, and safety can be assured, and that it is possible to grow essentially unlimited amounts of dopamine-producing nerve cells in the laboratory for transplantation, said a study, published in the Journal of Parkinson’s Disease.

“We are moving into a very exciting era for stem cell therapy. The first-generation cells are now being trialed and new advances in stem cell biology and genetic engineering promise even better cells and therapies in the future,” said Malin Parmar, postdoctoral candidate from the Lund University in Sweden.

Also Read- Here’s Why Facebook Was Labelled ‘Digital Gangsters’ by UK Lawmakers

“There is a long road ahead in demonstrating how well stem cell-based reparative therapies will work, and much to understand about what, where, and how to deliver the cells, and to whom,” said Parmar. (IANS)